Riskpilot← Back to searchSign inGet full accessIMMUNITRACK ApS
APSDissolvedCVR 32347908Lersø Parkallé 42, 4.Research and experimental development on natural sciences and engineering · NACE 7210Est. 201316 employees
Revenue 2024
DKK 142M
+706% vs 2023
EBITDA margin
99.8%
+1016% vs 2023
Equity ratio
85.6%
Financial strength
Net profit 2024
DKK 110M
+1216% vs 2023
| Revenue | DKK 142M | +706% |
| EBITDA | DKK 141,7M | +1016% |
| Net profit | DKK 110M | +1216% |
| Total assets | DKK 24,8M | -22% |
| Equity | DKK 21,2M | +0% |
| Employees | 16 | — |
Legal name
IMMUNITRACK ApS
CVR number
32347908
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
20. december 2013
Share capital
DKK 125.000
Employees
16 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør og bestyrelsesformanden i forening
Address
Lersø Parkallé 42, 4.
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -50 | 483 | 1.017 | 2.450 | -457 | 1.090 | 4.533 | 5.476 | 5.257 | 17.605 | 141.976 |
| Staff expenses | -0 | -422 | -676 | -166 | -2.344 | -2.394 | -3.994 | -3.711 | -4.452 | -4.914 | -308 |
| EBITDA | -50 | 61 | 341 | 2.284 | -2.801 | -1.304 | 540 | 1.765 | 805 | 12.691 | 141.668 |
| Depreciation & amort. | -18 | -29 | -28 | -107 | -191 | -199 | -218 | -754 | -996 | -967 | -1.615 |
| EBIT | -68 | 32 | 313 | 2.177 | -2.992 | -1.503 | 322 | 1.011 | -191 | 11.724 | 140.053 |
| Net financials | -0 | -2 | -7 | -24 | 44 | -70 | -266 | 272 | -134 | -952 | 971 |
| Profit before tax | -38 | 29 | 306 | 2.153 | -2.948 | -1.573 | 56 | 1.284 | -325 | 10.772 | 141.023 |
| Tax | 15 | 7 | 67 | 476 | -644 | -343 | -201 | 108 | -131 | 2.416 | 31.014 |
| Net profit | -53 | 23 | 239 | 1.677 | -2.303 | -1.230 | 257 | 1.176 | -194 | 8.356 | 110.009 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 202 | 693 | 1.113 | 5.050 | 8.902 | 7.257 | 12.493 | 15.550 | 21.096 | 31.709 | 24.769 |
| Equity | 27 | 49 | 288 | 3.545 | 6.108 | 4.878 | 7.672 | 10.160 | 12.846 | 21.202 | 21.212 |
| Long-term debt | 0 | 0 | 0 | 66 | 20 | 0 | 1.942 | 2.167 | 2.525 | 4.576 | 0 |
| Short-term debt | 175 | 644 | 767 | 956 | 2.773 | 2.378 | 2.878 | 3.223 | 5.052 | 3.771 | 3.195 |
| Total debt | 175 | 644 | 767 | 1.022 | 2.793 | 2.378 | 4.821 | 5.390 | 7.577 | 8.346 | 3.195 |
EBITDA margin
99.8%
This company
15.8%
Market median
+532% vs market
20152024
Equity ratio
85.6%
This company
38.2%
Market median
+124% vs market
20152024
Return on equity
518.6%
This company
18.4%
Market median
+2718% vs market
20152024
Net profit margin
77.5%
This company
8.1%
Market median
+857% vs market
20152024
Asset turnover
5.73×
This company
1.12×
Market median
+412% vs market
20152024
Debt / equity
0.17×
This company
0.62×
Market median
+73% vs market
20152024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-06-01 – 2023-12-31
- Annual report 2023Filed via CVR / Virk · Period 2022-06-01 – 2023-05-31
- Annual report 2022Filed via CVR / Virk · Period 2021-06-01 – 2022-05-31
- Annual report 2021Filed via CVR / Virk · Period 2020-06-01 – 2021-05-31
- Annual report 2020Filed via CVR / Virk · Period 2019-06-01 – 2020-05-31
- Annual report 2019Filed via CVR / Virk · Period 2018-06-01 – 2019-05-31
- Annual report 2018Filed via CVR / Virk · Period 2017-06-01 – 2018-05-31
- Annual report 2017Filed via CVR / Virk · Period 2016-06-01 – 2017-05-31
- Annual report 2016Filed via CVR / Virk · Period 2015-06-01 – 2016-05-31
- Annual report 2015Filed via CVR / Virk · Period 2013-12-20 – 2015-05-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PL Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
MC Chief Executive Officer | Chief Executive Officer | 2024 | — | — |
SP Management | Management | 2013 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2024 | — | — | |
| Chairman | 2023 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2021 | — | — | |
| Chairman | 2017 | — | — | |
| Board of Directors | 2018 | — | — | |
| Board of Directors | 2017 | — | — | |
| Board of Directors | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 15.0% | 15.0% | 2023 | |
| Individual | 15.0% | 15.0% | 2020 | |
Justesen Enterprises ApS | Company | 25.0% | 25.0% | 2022 |
ELI LILLY DANMARK A/S | Company | 100.0% | 100.0% | 2023 |
Bitter Sweet $ Symphony Holding ApS | Company | 66.7% | 66.7% | 2018 |
| Individual | 15.0% | 20.0% | 2019 | |
Licorne Enterprises ApS | Company | 25.0% | 25.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of IMMUNITRACK ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Philip Leo Johnson | Chief Executive Officer | 0 companies |
| Michael C Thompson | Chief Executive Officer | 0 companies |
| Stephan Pascal Thorgrimsen | Management | 0 companies |
| Christopher Henry Anderson | Board of Directors | 0 companies |
| Gordon James Brooks | Chairman | 0 companies |
| Stephen Clive Langford Gibbons | Board of Directors | 0 companies |
| Karin Absalonsen | Chairman | 0 companies |
| Sune Frederik Lamdahl Justesen | Chairman | 0 companies |
| Robin William Berryman Campbell | Board of Directors | 0 companies |
| Sune Frankild | Board of Directors | 0 companies |
| Li Chia Lim | Board of Directors | 0 companies |